Run time: 1 hour 38 minutes
Download handout: https://bit.ly/3LjP2Uk

In part 1 of a series on ketamine, patients with major depressive disorder often have limited response to first-line and second-line medications – that’s why novel pharmacological treatments are needed for treatment-resistant depression (TRD). Join Dr. Jennifer Dore as she discusses the mechanism of action for the use of ketamine for treatment resistant depression and explains dosing parameters and how to evaluate if ketamine will be a good therapeutic option for a patient. Dr. Dore will also discuss the pros and cons of compounded ketamine vs. Spravato® and how she works closely with her compounding pharmacist to provide the best care for her patients.